1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023

Summary

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

The new therapies entering the AMD market will be the main driver of growth in this market, with the wAMD drugs Fovista, squalamine, and abicipar pegol launching into the French market in 2017, 2018, and 2020, respectively. GlobalData estimates that the combined drug sales for ME and AMD in Italy during 2013 reached $348m.

Scope

- Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Macular Edema and Macular Degeneration market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table Of Contents

PharmaPoint: Macular Edema and Macular Degeneration - 5EU Drug Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 16
2.1 Related Reports 17
3 Disease Overview 19
3.1 Macular Degeneration Overview 19
3.1.1 Etiology and Pathophysiology 21
3.1.2 Classification 25
3.1.3 Symptoms and Diagnosis 27
3.2 Macular Edema Overview 30
3.2.1 Etiology and Pathophysiology 31
3.2.2 Classification 34
3.2.3 Symptoms and Diagnosis 35
4 Disease Management 38
4.1 Diagnosis and Treatment Overview 38
4.1.1 Macular Edema Diagnosis 38
4.1.2 Macular Degeneration Diagnosis 38
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 39
4.1.4 Clinical Practice 41
4.2 France 54
4.3 Germany 58
4.4 Italy 61
4.5 Spain 64
4.6 UK 67
5 Competitive Assessment 70
5.1 Overview 70
5.2 Product Profiles - Major Brands 71
5.2.1 Lucentis (ranibizumab) 71
5.2.2 Eylea (aflibercept) 81
5.2.3 Avastin (bevacizumab) 90
5.2.4 Macugen (pegaptanib sodium) 96
5.2.5 Visudyne (verteporfin) 99
5.2.6 Corticosteroid Implants 104
6 Unmet Need and Opportunity 115
6.1 Overview 115
6.2 Treatment for Dry AMD 116
6.2.1 Unmet Need 116
6.2.2 Gap Analysis 118
6.2.3 Opportunity 120
6.3 Longer-Acting Anti-VEGF Drug Therapy 122
6.3.1 Unmet Need 122
6.3.2 Gap Analysis 124
6.3.3 Opportunity 124
6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 125
6.4.1 Unmet Need 125
6.4.2 Gap Analysis 126
6.4.3 Opportunity 127
6.5 Less Invasive Drug Formulations 127
6.5.1 Unmet Need 127
6.5.2 Gap Analysis 128
6.5.3 Opportunity 129
6.6 Awareness and Earlier Patient Diagnosis 130
6.6.1 Unmet Need 130
6.6.2 Gap Analysis 131
6.6.3 Opportunity 131
6.7 Home Monitoring of AMD Progression 132
6.7.1 Unmet Need 132
6.7.2 Gap Analysis 133
6.7.3 Opportunity 134
7 Pipeline Assessment 136
7.1 Overview 136
7.2 Promising Drugs in Clinical Development 137
7.2.1 Abicipar pegol 139
7.2.2 Fovista 145
7.2.3 Squalamine 153
7.2.4 Lampalizumab 160
7.2.5 Emixustat 166
7.3 Promising Drugs in Early-Stage Development 172
7.3.1 Complement Inhibitors 172
7.4 Other Drugs in Development 174
7.5 Biosimilars 176
8 Market Outlook 178
8.1 Global 178
8.1.1 Drivers and Barriers - Global Issues 178
8.2 France 181
8.2.1 Forecast 181
8.2.2 Key Events 187
8.2.3 Drivers and Barriers 187
8.3 Germany 191
8.3.1 Forecast 191
8.3.2 Key Events 196
8.3.3 Drivers and Barriers 196
8.4 Italy 199
8.4.1 Forecast 199
8.4.2 Key Events 206
8.4.3 Drivers and Barriers 206
8.5 Spain 210
8.5.1 Forecast 210
8.5.2 Key Events 215
8.5.3 Drivers and Barriers 215
8.6 UK 218
8.6.1 Forecast 218
8.6.2 Key Events 224
8.6.3 Drivers and Barriers 224
9 Appendix 229
9.1 Bibliography 229
9.2 Abbreviations 254
9.3 Methodology 260
9.4 Forecasting Methodology 260
9.4.1 Diagnosed ME and AMD Patients 260
9.4.2 Percentage of Drug-Treated Patients 261
9.4.3 Drugs Included in Each Therapeutic Class 261
9.4.4 Launch and Patent Expiry Dates 261
9.4.5 General Pricing Assumptions 262
9.4.6 Individual Drug Assumptions 263
9.4.7 Pricing of Pipeline Agents 268
9.5 Primary Research - KOLs Interviewed for this Report 269
9.6 Primary Research - High-Prescribers Survey 270
9.7 About the Authors 271
9.7.1 Analyst 271
9.7.2 Therapy Area Director 271
9.7.3 Global Head of Healthcare 272
9.8 About GlobalData 273
9.9 Disclaimer 273

1.1 List of Tables

Table 1: ARM System Classification of AMD 26
Table 2: Symptoms of AMD 27
Table 3: National and International Treatment Guidelines for ME and AMD 40
Table 4: Most Prescribed Drugs for ME and AMD in the 5 EU Markets, 2013 41
Table 5: ME and AMD Disease Management - France 57
Table 6: ME and AMD Disease Management - Germany 60
Table 7: ME and AMD Disease Management - Italy 63
Table 8: ME and AMD Disease Management - Spain 66
Table 9: ME and AMD Disease Management - UK 69
Table 10: Leading Treatments for ME and AMD, 2014 71
Table 11: Product Profile - Lucentis 76
Table 12: Lucentis SWOT Analysis, 2014 81
Table 13: Approval Dates for Eylea 85
Table 14: Product Profile - Eylea 85
Table 15: Eylea — Common Adverse Reactions 89
Table 16: Eylea SWOT Analysis, 2014 90
Table 17: Product Profile - Avastin 94
Table 18: Avastin SWOT Analysis, 2014 96
Table 19: Product Profile - Macugen 98
Table 20: Product Profile - Visudyne 102
Table 21: Visudyne SWOT Analysis, 2014 103
Table 22: Product Profile - Ozurdex 106
Table 23: Product Profile - Iluvien 110
Table 24: Corticosteroid IVT Implants SWOT Analysis, 2014 114
Table 25: Unmet Needs and Opportunities in ME and AMD 116
Table 26: Promising Drugs in Clinical Development for ME and AMD 137
Table 27: Comparison of Drugs in Development for ME and AMD, 2014 138
Table 28: Product Profile - Abicipar pegol 141
Table 29: SWOT Analysis - Abicipar pegol, 2014 145
Table 30: Product Profile - Fovista 150
Table 31: SWOT Analysis - Fovista, 2014 153
Table 32: Product Profile - Squalamine 157
Table 33: SWOT Analysis - Squalamine, 2014 160
Table 34: Product Profile - Lampalizumab 163
Table 35: SWOT Analysis - Lampalizumab, 2014 166
Table 36: Product Profile - Emixustat 169
Table 37: SWOT Analysis - Emixustat, 2014 172
Table 38: Early-Stage Drugs in Clinical Development for ME and AMD, 2014 175
Table 39: ME and AMD Markets - Drivers and Barriers, 2013-2023 178
Table 40: Sales Forecast ($m) for ME in France, 2013-2023 183
Table 41: Sales Forecast ($m) for AMD in France, 2013-2023 185
Table 42: Key Events Impacting Sales for ME and AMD in France, 2013-2023 187
Table 43: ME and AMD Markets - Drivers and Barriers in France, 2013-2023 187
Table 44: Sales Forecast ($m) for ME in Germany, 2013-2023 192
Table 45: Sales Forecast ($m) for AMD in Germany, 2013-2023 194
Table 46: Key Events Impacting Sales for ME and AMD in Germany, 2013-2023 196
Table 47: ME and AMD Markets - Drivers and Barriers in Germany, 2013-2023 196
Table 48: Sales Forecast ($m) for ME in Italy, 2013-2023 202
Table 49: Sales Forecast ($m) for AMD in Italy, 2013-2023 204
Table 50: Key Events Impacting Sales for MME and AMD in Italy, 2013-2023 206
Table 51: ME and AMD Markets - Drivers and Barriers in Italy, 2013-2023 206
Table 52: Sales Forecast ($m) for ME in Spain, 2013-2023 211
Table 53: Sales Forecast ($m) for AMD in Spain, 2013-2023 213
Table 54: Key Events Impacting Sales for ME and AMD in Spain, 2013-2023 215
Table 55: ME and AMD Markets - Drivers and Barriers in Spain, 2013-2023 215
Table 56: Sales Forecast ($m) for ME in the UK, 2013-2023 220
Table 57: Sales Forecast ($m) for AMD in the UK, 2013-2023 222
Table 58: Key Events Impacting Sales for ME and AMD in the UK, 2013-2023 224
Table 59: ME and AMD Markets - Drivers and Barriers in the UK, 2013-2023 224
Table 60: Key Launch Dates 261
Table 61: Key Patent Expiries 262
Table 62: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 270

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 19
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 28
Figure 3: Color Fundus Photographs of Dry and Wet AMD 28
Figure 4: FAF Imaging of GA 29
Figure 5: Imaging of wAMD 30
Figure 6: CMT in DME 36
Figure 7: RVOs (BRVO and CRVO) on an FA 37
Figure 8: Increased CRT in ME-RVO 37
Figure 9: ME Clinical Treatment Flowchart 47
Figure 10: AMD Clinical Treatment Flowchart 54
Figure 11: Eylea's Clinical Development in DME and ME-BRVO 86
Figure 12: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME 111
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013-2023 139
Figure 14: Abicipar Pegol's Clinical Development in wAMD and DME 142
Figure 15: Clinical and Commercial Positioning of abicipar pegol 144
Figure 16: Fovista's Clinical Development in wAMD 150
Figure 17: Clinical and Commercial Positioning of Fovista 152
Figure 18: Squalamine's Clinical Development in wAMD and DME 157
Figure 19: Clinical and Commercial Positioning of squalamine 159
Figure 20: Lampalizumab's Development in wAMD 163
Figure 21: Clinical and Commercial Positioning of lampalizumab 165
Figure 22: Emixustat Clinical Development in dAMD 169
Figure 23: Clinical and Commercial Positioning of emixustat 171
Figure 24: Individual Drug Sales for ME in France, 2013-2023 184
Figure 25: Individual Drug Sales for AMD in France, 2013-2023 186
Figure 26: Individual Drug Sales for ME in Germany, 2013-2023 193
Figure 27: Individual Drug Sales for AMD in Germany, 2013-2023 195
Figure 28: Individual Drug Sales for ME in Italy, 2013-2023 203
Figure 29: Individual Drug Sales for AMD in Italy, 2013-2023 205
Figure 30: Individual Drug Sales for ME in Spain, 2013-2023 212
Figure 31: Individual Drug Sales for AMD in Spain, 2013-2023 214
Figure 32: Individual Drug Sales for ME in the UK, 2013-2023 221
Figure 33: Individual Drug Sales for AMD in the UK, 2013-2023 223

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.